Newsletter Tool

Today’s Big News

Jun 20, 2024

Jazz hits dud note as midphase essential tremor test misses endpoint

Taysha links gene therapy to motor gains in small Rett study

Biopharma dealmaking continues to rise, but M&A values hold steady: PwC

With iOnctura and Yellowstone, Syncona adds two cancer biotechs to growing portfolio

Private equity invests in trial sites as CRO consolidation continues: PitchBook

Featured

Jazz hits dud note as midphase essential tremor test misses endpoint

By Nick Paul Taylor

Jazz Pharmaceuticals hit a bum note Thursday, reporting the failure of a phase 2b essential tremor trial to meet its primary endpoint. But the drugmaker saw numeric improvements and is waiting on the data from another study rather than immediately bringing the curtain down on the program.

Taysha links gene therapy to motor gains in small Rett study

By Nick Paul Taylor

Taysha Gene Therapies has unfurled more data in the developmental disorder Rett syndrome, linking its gene therapy to improvements in the first adults and children to receive low doses of the candidate.

Biopharma dealmaking continues to rise, but M&A values hold steady: PwC

By James Waldron

Thanks to a flurry of dealmaking across the Christmas period and into the new year, it sure feels like both biotechs and Big Pharma have picked up the pace when it comes to hunting down fresh assets. After crunching the data, PwC has come to the same conclusion.

Revolutionizing cancer treatment: the potential of immune-modulating cancer vaccines

With iOnctura and Yellowstone, Syncona adds two cancer biotechs to growing portfolio

By James Waldron

Syncona has added two up-and-coming cancer companies to its portfolio, ensuring the biotechs are armed with a combined total of over $100 million in series A and B funds.

Private equity invests in trial sites as CRO consolidation continues: PitchBook

By Helen Floersh

Private equity dollars are flowing toward clinical trial sites as the industry conditions demand larger site networks, a new PitchBook analysis of first quarter 2024 deal activity shows.

In fight against knockoff weight loss meds, Eli Lilly accuses sellers of 'deceptive' advertising

By Kevin Dunleavy

Eli Lilly is stepping up its effort to combat the improper sale of compounded versions of its popular diabetes and weight loss drugs. The Indianapolis-based drugmaker is suing six wellness centers, medical spas and others that it claims are using "deceptive" advertising.

J&J's digital spree continues with Polyphonic 'social network' for surgeons

By Conor Hale

Designed as something of a private social network for clinicians, Polyphonic will allow users to share annotated video from procedures within their health system and tag in others for their input.

AHIP 2024: Not just a buzzword—payers envision AI’s future

By Noah Tong

Health insurance executives are captivated by artificial intelligences' use cases. Here's where they see advancements on the horizon.

Johnson & Johnson blueprints €125M plant upgrade as part of 5-year Italy investment

By Fraiser Kansteiner

Over the next five years, J&J Innovative Medicine will plug a projected 580 million euros ($621.7 million) into its Italian business, the company said in a press release. Of that sum, 125 million euros will go toward capacity upgrades and capability buildout at the company’s tablet manufacturing site at Latina in central Italy.

Fierce podcasts

Don’t miss an episode

'The Top Line': Inside this year’s ASCO: Biggest data drops, trends and the best exhibit booth

In this week's episode of "The Top Line," journalists from Fierce Biotech and Fierce Pharma discuss the most talked-about data drops at ASCO and share on-the-ground details, including their experience with Gilead’s virtual reality Trodelvy ride.

'The Top Line': A look at the top 10 pharma drug ad spenders

'Podnosis': Cybersecurity lessons from the Change Healthcare hack

Resources

Webinar

Enhance your long-term cell & gene therapy success with pDNA manufacturing solutions

Watch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies.

A Comprehensive and Flexible Approach to CMC for Fab and Fc-Fusion Development Programs

New molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more.

Presented by: Lonza

Whitepaper

Fresenius Medical Care gets 25x faster kidney disease insights

This detailed case study shows how Fresenius Medical Care achieved 25 times faster insights to help kidney disease patients, launching the world’s largest global database of dialysis care with fully anonymized patient data.

Sponsored by: Privacy Analytics, an IQVIA company

Whitepaper